Literature DB >> 31559337

Palliative chemotherapy in pancreatic cancer-treatment sequences.

Rami Abbassi1, Hana Algül1.   

Abstract

Pancreatic cancer belongs to the most deadly malignancies and is expected to become the second deadliest cancer by 2040. Still, in most of the cases the tumor is detected in a nonresectable or metastatic state and, untreated, the disease will progress rapidly. Even with chemotherapeutic treatment the prognosis is poor and the 5-year overall survival rate is less than 10%. Therefore, there is a need for proper therapeutic options for the palliative treatment of the disease. Despite great efforts to find new drugs for the treatment of pancreatic cancer, for a long time the therapy was limited to the use of gemcitabine with very limited benefit. Recently new chemotherapeutic regimens have been identified that helped to improve the overall survival significantly. In addition, even second-line therapies have been established. This review will provide an overview on the current standard of care, discusses possible treatment sequences and offer a perspective on future developments.

Entities:  

Keywords:  Pancreatic cancer; palliative chemotherapy; treatment options

Year:  2019        PMID: 31559337      PMCID: PMC6737397          DOI: 10.21037/tgh.2019.06.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  7 in total

1.  Comparison between B-mode ultrasonography and contrast-enhanced ultrasonography for the surveillance of early stage pancreatic cancer: a retrospective study.

Authors:  Jin Xu; Meng Zhang; Gang Cheng
Journal:  J Gastrointest Oncol       Date:  2020-10

2.  FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.

Authors:  Taylor J Allen-Coyle; Jin Niu; Eva Welsch; Neil T Conlon; Weylon Garner; Martin Clynes; Finbarr O'Sullivan; Robert M Straubinger; Donald E Mager; Sandra Roche
Journal:  AAPS J       Date:  2022-10-13       Impact factor: 3.603

Review 3.  Precision Therapy of Pancreatic Cancer: From Bench to Bedside.

Authors:  Katrin Jana Ciecielski; Alexandra Berninger; Hana Algül
Journal:  Visc Med       Date:  2020-10-06

Review 4.  Altered glycosylation in pancreatic cancer and beyond.

Authors:  Jan C Lumibao; Jacob R Tremblay; Jasper Hsu; Dannielle D Engle
Journal:  J Exp Med       Date:  2022-05-06       Impact factor: 17.579

5.  Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study.

Authors:  Lian Lian; Xiao-Ming Shen; Tie-Ao Huang; Da-Peng Li; Xian-Min Li; Shu-Guang Han; Xue-Fei Xu; Chun-Tao Ma; Chong Zhou
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

6.  Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis.

Authors:  Oliver Beetz; Akin Sarisin; Alexander Kaltenborn; Jürgen Klempnauer; Michael Winkler; Gerrit Grannas
Journal:  World J Surg Oncol       Date:  2020-08-20       Impact factor: 2.754

7.  Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer.

Authors:  Huiyang Wang; Wenxiu Ding; Hongwei Shi; Haiwei Bao; Yuting Lu; Tian An Jiang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.